Rare apoa5 promoter variants associated with paradoxical hdl cholesterol decrease in response to fenofibric acid therapy[s]

HIGHLIGHTS

• who: Ariel Brautbar from the Center for HumanUniversity of, **** London, Ontario, Canada have published the research work: Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy[S], in the Journal: (JOURNAL)
• what: The authors examined the association between rare genetic variants in the APOA5 gene region and change in HDL-C, apoA-I, and TG levels in response to FA alone and in combination with statins. The study was approved by the Institutional Review Board of Baylor College of Medicine, and informed consent was obtained by Abbott Laboratories . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.